Immunosurveillance against cancer and immunotherapy - Synergy or antagonism?

New England Journal of Medicine

Volumn 348, Issue 3, 2003, Pages 252-254

  Boon, Thierry ^a   Van Baren, Nicolas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER THERAPY; DENDRITIC CELL; EDITORIAL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VIRUS RECOMBINANT;

CANCER VACCINES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES;

EID: 0037448371     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe020165     Document Type: Editorial

References (8)

1. Burnet M. Cancer - a biological approach. III. Viruses associated with neoplastic conditions. BMJ 1957;1:841-7.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
3. Qin Z, Kim HJ, Hemme J, Blankenstein T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 2002;195:1479-90.
4. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
5. Seiter S, Monsurro V, Nielsen MB, et al. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother 2002;25:252-63.
6. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
7. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
8. Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001;98:10290-5.